Gunjan Bhardwaj, the Founder and CEO of Innoplexus, a company that uses AI and Big Data to make drug development faster and drug prices less expensive joins Enterprise Radio. Summary: If you're an entrepreneur working with over-hyped technologies, you have to find a way to cut through the hype so that people will take your product seriously. The best way to do this is to focus on solving real, practical problems. The technology is only a means to an end -- it's only valuable insofar as it solves a real problem that people care about. Gunjan Bhardwaj founded Innoplexus 7 years ago with the goal of revolutionizing healthcare with AI and Big Data.

Cutting-edge technologies are increasingly improving pharma's R&D processes, which will reduce costs and, in turn, benefit patients, says Gunjan Bhardwaj. It's no secret that drug prices are a controversial issue. Just last week, US President Trump called high drug prices an "injustice" and vowed to make the issue a priority for his administration. In the face of such pressure, pharmaceutical companies are eager to reduce the cost of drug development so that consumer prices can be lowered without sacrificing profit margin. Fortunately, cutting-edge technologies such as AI, blockchain, and big data have the potential to eliminate costly inefficiencies in the drug discovery and development process.

The increased use of artificial intelligence and machine learning is shifting the paradigm of medical research and treatment. These advanced technologies are providing researchers real-time access to every white paper and clinical case study conducted on a genetic disorder. Being able to develop such an elaborate database of information allows researchers to not only understand the full scope of a medical condition, but further shorten the amount of time it takes to develop a cure. Founded in 2011 by Gunjan Bhardwaj and Gaurav Tripathi, Innoplexus is a technology and product development company focused on solving complex challenges in the pharmaceutical and life sciences industries. Their end-to-end platform for Life Sciences research uses artificial intelligence to generate smart data and insights to assist in the discovery, clinical development and regulatory compliance of pharmaceutical medicine.

The increased use of artificial intelligence and machine learning is shifting the paradigm of medical research and treatment. These advanced technologies are providing researchers real-time access to every white paper and clinical case study conducted on a genetic disorder. Being able to develop such an elaborate database of information allows researchers to not only understand the full scope of a medical condition, but further shorten the amount of time it takes to develop a cure. Founded in 2011 by Gunjan Bhardwaj and Guarav Tripathi, Innoplexus is a technology and product development company focused on solving complex challenges in the pharmaceutical and life sciences industries. Their end-to-end platform for Life Sciences research uses artificial intelligence to generate smart data and insights to assist in the discovery, clinical development and regulatory compliance of pharmaceutical medicine.